Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis.
Multiple sclerosis causing a partial sixth nerve palsy.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
MARGA: Multispectral Adaptive Region Growing Algorithm for brain extraction on axial MRI.
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis.
The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
European medicines agency's committee for medicinal products for human use issues positive opinion on marketing authorisation application for Fampyra
Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study.
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report.
Product Insert, Amiloride HCl Tablets
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Individual variation of human sphingosine 1-phosphate receptor 1 coding sequence leads to heterogeneity in receptor function and drug interactions.
MYRAC Rx
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
[Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic].
Sex effects on inflammatory and neurodegenerative processes in multiple sclerosis.
A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
Plasma exchange in severe attacks of neuromyelitis optica.
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study.
Pages
« first
‹ previous
…
124
125
126
127
128
129
130
131
132
…
next ›
last »